ロード中...
Vismodegib
Vismodegib (GDC-0449), an orally bioavailable small molecule inhibitor of Hedgehog signaling, was recently approved by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma that is either metastatic or locally advanced in patients who are not candidates for surgical resecti...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383648/ https://ncbi.nlm.nih.gov/pubmed/22653209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrd3753 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|